|
|||||
|
|
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers |
|
| Authors: | Lucy Yang Joseph Cheriyan David D. Gutterman Ruth J. Mayer Zsuzsanna Ament Jules L. Griffin Aili L. Lazaar David E. Newby Ruth Tal-Singer Ian B. Wilkinson |
| Affiliation: | 1. Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Addenbrooke’s Hospital, Cambridge, England;2. Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England;3. Clinical Unit Cambridge, GSK R&D, Cambridge, England;4. MRC Human Nutrition Research, Elsie Widdowson Laboratory; and Department of Biochemistry, University of Cambridge, Cambridge, England;5. Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI;6. GSK R&D, King of Prussia, PA;7. British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland |
| Abstract: | |
| Keywords: | clinical trial COPD EETs endothelial function smokers soluble epoxide hydrolase inhibitor CYP cytochrome P450 DHET dihydroxyepoxyeicosatrienoic acid EC50 half maximal effective concentration EDHF endothelium-derived hyperpolarizing factor EET epoxyeicosatrienoic acid LNAME L-nitroarginine methyl ester LNMMA NG-monomethyl-L-arginine NFκB nuclear factor kappa light-chain enhancer of activated B cells NO nitric oxide PAI-1 plasminogen activator inhibitor type 1 sEH soluble epoxide hydrolase SNP sodium nitroprusside tPA tissue plasminogen activator |
| 本文献已被 ScienceDirect 等数据库收录！ | |